81. Next steps in unlocking the power of computational biology for I-O target identification and validation. Issue 5 (2021) Authors: Wang, Ning Journal: Immuno-oncology insights Issue: Volume 2:Issue 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
82. Old data, new tools: leveraging routinely acquired patient data to address current challenges in I–O. Issue 7 (2022) Authors: McGuigan, Ròisin Journal: Immuno-oncology insights Issue: Volume 3:Issue 7(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
83. Optimizing antibody discovery strategy for clinical success of next-gen immuno-oncology therapeutics. Issue 2 (2020) Authors: Roodink, Ilse; Ott, Patrick; Senutovitch, Nina Journal: Immuno-oncology insights Issue: Volume 1:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
84. Outlook on manufacturing adoptive cell therapies for cancer immunotherapy. Issue 2 (2021) Authors: Wang, Xiuyan; Riviere, Isabelle Journal: Immuno-oncology insights Issue: Volume 2:Issue 2(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
85. Overcoming purification challenges in antibody therapeutics manufacturing with subdomain-specific affinity solutions. Issue 5 (2021) Authors: Sierkstra, Laurens Journal: Immuno-oncology insights Issue: Volume 2:Issue 5(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
86. Patient-centered care in immuno-oncology: current progress & opportunities when considering safety & tolerability. Issue 6 (2022) Authors: Adessi, Céline; Rüttinger, Dominik Journal: Immuno-oncology insights Issue: Volume 3:Issue 6(2022) Page Start: 305 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
87. Powering antitumor immunity: challenges & promise at the intersection of immunometabolism & cancer immunotherapy. Issue 10 (2022) Authors: Lopez-Ichikawa, Maya; Levine, Lauren S Journal: Immuno-oncology insights Issue: Volume 3:Issue 10(2022) Page Start: 479 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
88. Preclinical models for development of immune–oncology therapies. Issue 8 (2022) Authors: Wang, Yufei; Shelton, Sarah E; Kastrunes, Gabriella; Barbie, David A; Freeman, Gordon J; Marasco, Wayne A Journal: Immuno-oncology insights Issue: Volume 3:Issue 8(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
89. Progress and challenges for T cell receptor engineered T cells for cancer therapy. Issue 1 (2020) Authors: Stromnes, Ingunn M Journal: Immuno-oncology insights Issue: Volume 2:Issue 1(2021) Page Start: 35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
90. Promise & challenges in discovering cellular immunotherapies & T cell engagers for solid tumor indications. Issue 4 (2022) Authors: McCall, David Journal: Immuno-oncology insights Issue: Volume 3:Issue 4(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗